Healionics is focused on advancing dialysis access solutions for patients with kidney failure through its innovative STARgraft synthetic blood vessel. This vascular graft is designed to provide a safer and more reliable means of bloodstream access, addressing the significant challenges associated with current dialysis methods, which often involve high risks of occlusion and infection. The STARgraft has shown superior performance in human studies, demonstrating enhanced resistance to these common complications. This improvement is crucial for patients who require frequent blood filtration, as it aims to enhance their health, longevity, and overall quality of life while also reducing treatment costs.

The foundation of Healionics' technology lies in its proprietary STAR® (Sphere Templated Angiogenic Regeneration) biomaterial scaffold. This breakthrough material is engineered to optimize biointegration and tissue regeneration by achieving an ideal pore size and structure that promotes angiogenesis—the formation of new blood vessels—while minimizing the foreign body response and tissue scarring. The development of this advanced synthetic biomaterial reflects Healionics' commitment to innovation in the medical field, supported by collaborations with leading organizations in kidney treatment and dialysis technology.

United States

Healionics is addressing the critical need for safer, more reliable means of bloodstream access to perform dialysis in patients with kidney failure.  Our STARgraft vascular graft (synthetic blood vessel) is designed to resist the problems of occlusion and infection suffered by current devices.  We also have an exciting product pipeline based on our platform STAR® biomaterial, which has a unique ability to prevent two serious problems that affect all implantable devices:  scarring and infection.  The company is currently conducting human studies of STARgraft and has 36 patents issued or pending.

Healionics

Company Details